Journal article
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial
NC Tebbutt, TJ Price, DA Ferraro, N Wong, AS Veillard, M Hall, KM Sjoquist, N Pavlakis, A Strickland, SC Varma, P Cooray, R Young, C Underhill, JA Shannon, V Ganju, V Gebski
British Journal of Cancer | Cancer Research UK | Published : 2016
DOI: 10.1038/bjc.2015.440
Abstract
Background:This randomised phase II study evaluated the efficacy and safety of panitumumab added to docetaxel-based chemotherapy in advanced oesophagogastric cancer.Methods:Patients with metastatic or locally recurrent cancer of the oesophagus, oesophagogastric junction or stomach received docetaxel and a fluoropyrimidine with or without panitumumab for 8 cycles or until progression. The primary end point was response rate (RECIST1.1). We planned to enrol 100 patients, with 50% expected response rate for combination therapy.Results:A total of 77 patients were enrolled. A safety alert from the REAL3 trial prompted a review of data that found no evidence of adverse outcomes associated with pan..
View full abstractGrants
Funding Acknowledgements
Amgen Australia and Sanofi Australia provided funding to support the study. Neither company was involved in the study design, or data collection, analysis or interpretation. The content of the manuscript and the decision to submit was made independently by the authors.